Abstract: Trabectedin （Yondelis■） is a new non-platinum antineoplastic drug with a unique antitumor mechanism. It′s main side effect is the reversible liver injury, and it′s cardiac toxicity is low. Trabectedin can be applied with anthracycline-based drugs in the treatment of recurrent ovarian cancer. The optional treatment clinically include：single drug 3 weeks plan，single drug weekly therapy，combined anthracycline-based drugs，the best effect is the in combinational scheme. Trabectedin make satisfied curative effect in platinum sensitive recurrent ovarian cancer，especially treatment-free interval （TFI） 6-12 month. The platinum resistance and refractory ovarian cancer curative effect is not obvious. Application of Trabectedin can extend the TFI ,as to create conditions for using platinum drugs again.

Key words: Ovarian neoplasms, Carcinoma, Antineoplastic combined chemotherapy protocols, Trabectedin, Platinum-free interval